Solara Active Pharma Sciences Ltd (SOLARA) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management has delayed the final decision on the Ibuprofen business strategic review by another 12 weeks, maintaining all options are still under consideration.
- The company is on track to file five DMFs in FY27, signaling a significant revitalization of its R&D pipeline after a multi-year pause.
- The sharp increase in trade receivables was attributed to higher sales and logistical delays, with management confirming no adverse changes to customer payment terms.
Performance Overview
- Delivered the best quarter in approximately five years across all key profitability metrics: gross margin, EBITDA, and PAT.
- Achieved significant year-on-year revenue growth of 33%, driven by strong performance in the base business.
- The core base business continued its growth trajectory, with revenues increasing 37% YoY to 327 crores.
- Successfully completed a regulatory audit by ANVISA for the Mangalore facility in August, following a similar successful audit at the Cuddalore facility in May.
- Balance sheet strengthened significantly, with net debt reduced by 114 crores during the first half of FY27.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.